Sarah Abraham provides economic and financial analysis in antitrust, healthcare, and life sciences matters. In antitrust and competition litigation, Dr. Abraham has analyzed liability and damages issues pertaining to allegations of price fixing, monopolization, and anticompetitive conduct. She has substantial merger review experience and consults to government agencies and merging parties on market definition, market power, and competitive effects. Dr. Abraham works with attorneys across all phases of litigation and government and regulatory investigations and supports experts through discovery and trial.
Dr. Abraham has published research in peer-reviewed journals. In 2022, her coauthored article on dynamic treatment effects in event studies received the Aigner Award for Best Empirical Paper in the Journal of Econometrics.
Antitrust and competition
Dr. Abraham has analyzed large, proprietary datasets in high-profile matters involving antitrust and mergers in the healthcare and life sciences industry, including Sidibe et al. v. Sutter Health. She coauthored comments that were submitted to the Multilateral Pharmaceutical Merger Task Force on the varied effects of mergers on innovation.
Dr. Abraham’s other experience includes:
- Performing empirical analyses regarding liability and damages in alleged price fixing matters
- Evaluating the reliability of proposed damages models to assess allegations of monopolistic behavior in digital content distribution and payments markets
- Analyzing alleged anticompetitive conduct and damages
Dr. Abraham speaks on antitrust and competition issues related to healthcare and life sciences, including at the American Conference Institute’s summit on biosimilars and innovator biologics.
Dr. Abraham has consulted on nonhorizontal mergers for both the Department of Justice (DOJ) and merging parties. She has supported experts and counsel in matters involving market definition, market power, and competitive effects. In addition, Dr. Abraham has evaluated the reliability of survey results in the context of a merger.
In addition to her antitrust and merger work, Dr. Abraham consults on matters involving higher education, technology, and finance. Representative experience includes:
- Evaluating the proposed theory of harm in a class action involving tuition payments to higher education institutions during the COVID-19 pandemic
- Analyzing class certification issues in a Racketeer Influenced and Corrupt Organizations (RICO) class action related to energy policy
- Evaluating damages models for a residential mortgage-backed securities (RMBS) class action
- Quantifying the value of claims asserted to inform asset allocation across claimants in a bankruptcy
Before joining Cornerstone Research, Dr. Abraham was a predoctoral fellow with Opportunity Insights at Harvard University. She was awarded the NBER Health and Ageing Pre-Doctoral Fellowship and Castle Krob Fellowship for her doctoral research at the Massachusetts Institution of Technology.
Cornerstone Research Staff and Affiliated Experts Submit Comments on the Joint FTC-DOJ Draft Merger Guidelines
Cornerstone Research Announces Promotions to Principal
EC Investigation into Cloud Technology Company Merger
United States et al. v. UnitedHealth Group Incorporated et al.
Sidibe et al. v. Sutter Health
Cornerstone Research Staff and Experts Submit Comments to Multilateral Pharmaceutical Merger Task Force